A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart-Reference-Cited by-同舟云学术

A randomised, partially observer blind, multicentre, head-to-head comparison of a two-dose regimen of Baxter and GlaxoSmithKline H1N1 pandemic vaccines, administered 21 days apart

Published:2010-12 Issue:55 Volume:14 Page:
ISSN:1366-5278
Container-title:Health Technology Assessment
language:en
Short-container-title:Health Technol Assess

Author:

Nicholson KG¹,Abrams KR,Batham S,Clark TW,Hoschler K,Lim WS,Medina M,Nguyen-Van-Tam JS,Read RC,Warren FC,Zambon M

Affiliation:

1. Infectious Diseases Unit, Vaccine Evaluation Centre, University Hospitals of Leicester NHS Trust and Department of Inflammation, Infection and Immunity, University of Leicester, Leicester, UK

Funder

Health Technology Assessment programme

Publisher

National Institute for Health Research

Subject

Health Policy

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam;Vaccine;2018-11

2. Uptake and effectiveness of influenza vaccine in those aged 65 years and older in the United Kingdom, influenza seasons 2010/11 to 2016/17;Eurosurveillance;2018-09-27

3. Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011;Emerging Infectious Diseases;2012-11

4. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation;Vaccine;2012-11

5. Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals;BMC Immunology;2012-08-31